Alternatively, miR‐129‐3p has been reported to inhibit the NHEJ pathway—via the inhibition of XRCC4 SUMOylation—by targeting the SUMO‐activating enzyme SAE1 and repressing the progression of human gastric cancer [49]. The gene discussed is SAE1; the disease is gastric cancer.